BioPharm Systems Named to the 2010 Inc. 500:5000 List of Fastest-Growing Companies in the U.S.
BioPharm Systems announced that it has been named to Inc. magazine's list of the fastest-growing private companies in the United States for 2010. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. BioPharm Systems was recognized for its 60 percent three-year growth rate.
"We are honored to be named among the many other prestigious companies in America," said Alex Sefanov, president and CEO of BioPharm Systems. "BioPharm has been growing at a consistent rate for many years. Our team continues to develop and provide new solutions in order to meet our clients' needs. This past year we launched a Siebel Clinical Trial Management System (CTMS) accelerator called ASCEND, and it has been generating a lot of interest due to its robust features, cost-effectiveness, and fast implementation process. We also have developed several other solutions, including Accel-Transfer, which is a tool that extracts, transforms, and loads data from one safety application into another.
BioPharm Systems, an Oracle Gold Partner specializing in Oracle Health Sciences' suite of clinical and safety applications, opened an office in the United Kingdom earlier this year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
